gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LUNGHealthcareSurgical Instruments

Pulmonx Corporation Common Stock (LUNG)

$2.83+4.04%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.83▲ 64.53% in range
Nov 4, 2025Low $1.17 · High $3.17Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Pulmonx closed at $2.83 on Nov 4, up 4.04%, 10.6% below its 52-week closing high. Volume of 984.1K shares was 0.89× its 20-day average (close to normal).

Split-adjusted performance: +59.0% over one month, +119.4% over six months, +54.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $22.76M, down 4.6% from a year earlier, with a net margin of -44.3%.

Short interest was 698.6K shares at the Oct 15 settlement, down 13.0% from the prior report (1.8% of float, 2.5 days to cover).

Market cap$121.5M42.9M shares
Revenue · quarter$22.8M−4.6% YoY
Diluted EPS$-0.24—
P/E · TTM—P/S 1.4×
Net margin-44.3%Gross 78.0%
Dividend yieldNone
52-week range1.17 – 3.17−10.6% from high
Volume984.1K0.89× 20-day avg
Volatility · 60d96.9%Annualised
Short % of float1.8%2.5 days to cover
Net cash$18.3MCash $55.8M
Next earnings—Not scheduled
Split-adjusted performance
1W +12.3%1M +59.0%3M +38.0%6M +119.4%YTD +28.1%1Y +54.6%3Y −64.1%5Y −92.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum94
Revenue growth14
Net margin33
Value (low P/E)—
Size39

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short698.6K−13.0% vs prior
Days to cover2.5Settled Oct 15
% of float1.8%
Short vol. 10d43.8%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LUNGPulmonx$2.83+4.04%+119.4%−4.6%−44.3%—$121.5M
APYXApyx Medical$2.59−0.38%−11.3%+22.1%−23.4%—$109.1MCompare
KRMDKORU Medical Systems, Inc. Common Stock (DE)$3.27+5.48%−18.5%+18.2%2.1%—$151.0MCompare
LUCDLucid Diagnostics$0.4451+8.83%−58.8%+26.7%−998.3%—$85.0MCompare
MBOTMicrobot Medical$1.14+4.59%−47.9%—−2334.9%—$76.6MCompare
PDEXPro-Dex Inc New$63.44+5.31%+8.4%+11.0%14.8%16.9$203.0MCompare
SKINSkinHealth Systems$11.05+6.76%−40.8%−7.8%−3.7%—$72.0MCompare
LNSRLENSAR$5.84+4.85%+8.4%+18.4%10.7%4.6$71.7MCompare
STIMNeuronetics$2.71+19.69%+41.6%+9.1%−8.3%—$206.1MCompare

News about Pulmonx

All news →
All You Need to Know About Pulmonx (LUNG) Rating Upgrade to BuyZacks Investment Research · 5d ago▲ PositivePulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research · Oct 27, 2026Neutral

Quick answers

What does Pulmonx do?
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches.
What is LUNG's market cap?
$121.54M, based on the Nov 4 close of $2.83.
Does Pulmonx pay a dividend?
No regular cash dividend has been paid in the last year.
How much of LUNG is sold short?
698.6K shares, 1.8% of float, as of Oct 15, 2026.
What sector is LUNG in?
Healthcare, in the Surgical Instruments industry.

About Pulmonx

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

HQ: Redwood City, CA296 employeesListed Oct 1, 2020pulmonx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology